Which GLP-1 Drug Is Best for Weight Loss? (2026 Guide)
There is no single "best" GLP-1 drug — the right choice depends on your specific health goals, insurance coverage, and whether you need a drug that is available now or can wait for pipeline options. This guide covers every major GLP-1 and incretin-based weight loss drug, from approved medications to next-generation treatments in clinical trials.
GLP-1 Drug Landscape: Single to Triple Agonists
The field has progressed rapidly from single receptor agonists to multi-receptor combinations, with each generation producing more weight loss:
Single agonists (GLP-1 only): Semaglutide (Ozempic/Wegovy) targets the GLP-1 receptor to reduce appetite and slow gastric emptying. These were the first generation and remain the most widely prescribed.
Dual agonists (GLP-1 + GIP): Tirzepatide (Mounjaro/Zepbound) adds GIP receptor agonism, which enhances insulin secretion and may affect fat metabolism. Produces about 50% more weight loss than semaglutide in head-to-head trials.
Triple agonists (GLP-1 + GIP + Glucagon): Retatrutide adds glucagon receptor agonism, which increases energy expenditure through thermogenesis and promotes liver fat reduction. Produces the most weight loss of any drug tested.
Combination therapies (Amylin + GLP-1): CagriSema combines two separate drugs targeting amylin and GLP-1 pathways for additive appetite suppression.
Master Comparison Table
| Drug | Type | Max Weight Loss | Status | Oral Option |
|---|---|---|---|---|
| Semaglutide (Wegovy/Ozempic) | GLP-1 | -14.9% (STEP 1) | FDA approved | Yes |
| Tirzepatide (Zepbound/Mounjaro) | GLP-1 + GIP | -22.5% (SURMOUNT-1) | FDA approved | No |
| CagriSema | Amylin + GLP-1 | -22.7% (REDEFINE 1) | NDA filed (2025) | No |
| Retatrutide | GLP-1 + GIP + Glucagon | -28.7% (TRIUMPH-4) | Phase 3 | No |
| Orforglipron | GLP-1 (oral, non-peptide) | -12.4% (ATTAIN-1) | Phase 3 | Yes (daily pill) |
Interactive Comparison Tool
GLP-1 Drug Comparison Tool
Select 2-3 drugs to compare side by side. Click a drug to add or remove it.
Max Weight Loss
| Feature | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Type | Triple | Dual | Single |
| Brand Names | Not yet named | Mounjaro, Zepbound | Ozempic, Wegovy, Rybelsus |
| Manufacturer | Eli Lilly | Eli Lilly | Novo Nordisk |
| Mechanism | GLP-1 + GIP + Glucagon triple receptor agonist | GLP-1 + GIP dual receptor agonist | GLP-1 receptor agonist |
| Receptors | GLP-1, GIP, Glucagon | GLP-1, GIP | GLP-1 |
| FDA Status | Pipeline | FDA Approved | FDA Approved |
| Max Weight Loss | -28.7% (68 weeks) | -22.5% (72 weeks) | -14.9% (68 weeks) |
| Key Trial | TRIUMPH-4 | SURMOUNT-1 | STEP 1 |
| Dosing | Once weekly (injection) | Once weekly (injection) | Once weekly (injection) or daily (oral) |
| Oral Option | No | No | Yes |
| Monthly Cost | Not yet priced | $1,059 (list) / ~$550 (LillyDirect) | $1,349 (list) / ~$500 (savings program) |
| Key Advantage | Largest weight loss in any trial + liver fat reduction | Largest weight loss of any approved drug | Proven cardiovascular protection (SELECT trial) |
Disclaimer: Weight loss results are from separate clinical trials with different populations and cannot be directly compared. Only head-to-head trials (like SURMOUNT-5) provide definitive comparisons. This tool is for informational purposes only and does not constitute medical advice.
Which Drug Is Best for Your Priority?
Best for Maximum Weight Loss
Retatrutide (pipeline) produced -28.7% weight loss in TRIUMPH-4 — the largest result for any anti-obesity medication. Among approved drugs, tirzepatide (Zepbound) holds the record at -22.5%.
If maximum weight loss is the primary goal and you can access approved medications now, Zepbound is the current leader. If you can wait or enroll in a clinical trial, retatrutide may produce more.
Learn more: Retatrutide vs Zepbound | Zepbound vs Wegovy
Best for Proven Cardiovascular Protection
Semaglutide (Wegovy) is the only GLP-1 drug with proven cardiovascular outcomes data. The SELECT trial showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, CV death) in adults with obesity and established cardiovascular disease.
Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. Retatrutide's (TRIUMPH-Outcomes) has started but won't report for years.
Learn more: Ozempic vs Wegovy | Retatrutide and Heart Health
Best Oral Option
Oral Wegovy (semaglutide tablets, approved 2025) is the first oral GLP-1 drug specifically approved for weight loss. It produced -15.1% weight loss in OASIS 1 — comparable to the injectable form.
Orforglipron (pipeline) is a daily oral pill that does not require fasting or water restrictions. It is a small-molecule GLP-1 agonist — not a peptide — making it cheaper to manufacture. FDA filing expected 2025-2026.
Learn more: Retatrutide vs Orforglipron | Oral vs Injection
Best for Diabetes + Weight Loss
Tirzepatide (Mounjaro) has the strongest combined glucose control and weight loss data. In SURPASS-2, it reduced HbA1c by up to -2.58% and up to 46% of patients achieved a normal HbA1c (below 5.7%). It was also superior to semaglutide (Ozempic) head-to-head.
Learn more: Mounjaro vs Ozempic | Tirzepatide vs Semaglutide
Best for Liver Fat Reduction
Retatrutide (pipeline) produced up to 82.4% liver fat reduction in its Phase 2 sub-study — the strongest result for any drug tested for fatty liver disease. The glucagon receptor agonism drives hepatic fat oxidation in a way that GLP-1-only drugs do not match.
The dedicated TRIUMPH-MASLD Phase 3 trial is currently enrolling.
Learn more: Retatrutide and Fatty Liver | What Is Retatrutide?
Retatrutide: The Next Generation
Retatrutide is the first triple agonist — targeting GLP-1, GIP, and glucagon receptors simultaneously. It is being developed by Eli Lilly (the same company behind Mounjaro/Zepbound).
Key advantages over current approved drugs:
- 28.7% weight loss — 6+ percentage points more than tirzepatide
- 82.4% liver fat reduction — no approved drug matches this
- Glucagon-driven energy expenditure — attacks obesity from both sides (reduced intake + increased burn)
Retatrutide is not yet FDA-approved. Phase 3 results began reporting in December 2025, with NDA filing expected in 2026 and potential approval in 2027.
Learn more: What Is Retatrutide? | Retatrutide Clinical Trials | FDA Approval Timeline
Frequently Asked Questions
Which GLP-1 drug is best for weight loss?
For maximum weight loss among approved drugs, tirzepatide (Zepbound) at -22.5%. Among pipeline drugs, retatrutide at -28.7%. However, the "best" choice depends on individual factors including insurance coverage, cardiovascular risk, whether you prefer oral dosing, and availability.
What is the most effective weight loss drug in 2026?
Among FDA-approved drugs, tirzepatide (Zepbound/Mounjaro) produces the most weight loss (-22.5% in SURMOUNT-1). Retatrutide has produced -28.7% in Phase 3 trials but is not yet approved. CagriSema (-22.7%) has an NDA under review.
Is there a GLP-1 weight loss pill?
Yes. Oral Wegovy (semaglutide tablets) was FDA-approved in 2025 for weight loss — the first oral GLP-1 for this indication. Orforglipron, a daily oral GLP-1 pill from Eli Lilly, is in Phase 3 trials.
What is a triple agonist?
A triple agonist activates three hormone receptors simultaneously. Retatrutide targets GLP-1 (appetite suppression), GIP (insulin and fat metabolism), and glucagon (energy expenditure and liver fat reduction). It produces more weight loss than single or dual agonists.
How do I choose between Ozempic, Wegovy, Mounjaro, and Zepbound?
Ozempic and Wegovy are the same drug (semaglutide) — Ozempic for diabetes, Wegovy for weight loss. Mounjaro and Zepbound are the same drug (tirzepatide) — Mounjaro for diabetes, Zepbound for weight loss. If your primary goal is weight loss, Zepbound produces more weight loss than Wegovy. If cardiovascular protection matters, Wegovy has proven CV data. See our detailed comparisons for more.
What GLP-1 drugs are coming in 2026-2027?
CagriSema (amylin + GLP-1 combo by Novo Nordisk) has an NDA under review with possible approval in 2026. Orforglipron (oral GLP-1 pill by Lilly) may file in 2025-2026. Retatrutide (triple agonist by Lilly) is expected to file in 2026 with potential approval in 2027.
Can you use GLP-1 drugs for weight loss without diabetes?
Yes. Several GLP-1 drugs are FDA-approved specifically for weight loss in adults without diabetes. Wegovy (semaglutide) and Zepbound (tirzepatide) are both approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. You do not need to have type 2 diabetes to be prescribed these medications. Retatrutide is also being studied primarily in non-diabetic obesity populations.
How do GLP-1 drugs work for weight loss?
GLP-1 receptor agonists work by mimicking the natural GLP-1 hormone, which reduces appetite, slows gastric emptying (so you feel full longer), and improves blood sugar control. Newer drugs add additional receptor targets: tirzepatide also activates the GIP receptor, and retatrutide activates GIP and glucagon receptors too. More receptor targets generally means more weight loss. The glucagon receptor in particular increases energy expenditure, which is why retatrutide produces the largest weight loss results.
What are the different types of GLP-1 agonists for weight loss?
GLP-1 agonists for weight loss fall into several categories. Single agonists like semaglutide (Wegovy/Ozempic) target only GLP-1. Dual agonists like tirzepatide (Zepbound/Mounjaro) target GLP-1 and GIP. Triple agonists like retatrutide target GLP-1, GIP, and glucagon. Combination therapies like CagriSema pair a GLP-1 agonist with an amylin analog. There are also oral options: oral Wegovy (semaglutide tablets) and the pipeline drug orforglipron. Each type offers different trade-offs between weight loss efficacy, convenience, and availability.
Sources
- Jastreboff, A.M., et al. (2022). SURMOUNT-1 (tirzepatide). NEJM. DOI: 10.1056/NEJMoa2206038
- Wilding, J.P.H., et al. (2021). STEP 1 (semaglutide). NEJM. DOI: 10.1056/NEJMoa2032183
- Eli Lilly. (2025). TRIUMPH-4 results. Press release.
- Aronne, L.J., et al. (2025). REDEFINE 1 (CagriSema). NEJM. DOI: 10.1056/NEJMoa2502081
- Lincoff, A.M., et al. (2023). SELECT trial (semaglutide CV outcomes). NEJM. DOI: 10.1056/NEJMoa2307563
- Knop, F.K., et al. (2023). OASIS 1 (oral semaglutide). The Lancet. DOI: 10.1016/S0140-6736(23)01185-6
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All drugs mentioned are prescription medications or investigational compounds. Consult your healthcare provider for personalized medical decisions.
This site is not affiliated with Eli Lilly, Novo Nordisk, or any pharmaceutical manufacturer.
Sources
- SURMOUNT-1 (tirzepatide)
NEJM
- STEP 1 (semaglutide)
NEJM
- TRIUMPH-4 results
Eli Lilly
Related reading
GLP-1 Drug Comparison Tool: Compare Weight Loss Drugs Side by Side
Interactive comparison tool for GLP-1 weight loss drugs. Select 2-3 drugs to compare mechanism, efficacy, cost, and status.
Zepbound vs Wegovy: Which Weight Loss Drug Is Better?
Zepbound produced -20.2% vs Wegovy's -13.7% weight loss in the SURMOUNT-5 head-to-head trial. Full comparison of cost, side effects, and CV data.
Tirzepatide vs Semaglutide: Complete Comparison (2026 Data)
Tirzepatide vs semaglutide with SURMOUNT-5 head-to-head data: -20.2% vs -13.7% weight loss. Full comparison of efficacy, side effects, and access.